• Disabled-2 (Dab2) phosphorylation status in thrombin signaling of human platelet was investigated.
Essentials
• Disabled-2 (Dab2) phosphorylation status in thrombin signaling of human platelet was investigated.
• Ser723 was the major Dab2 phosphorylation site in human platelets stimulated by thrombin.
• Dab2 S723 phosphorylation (pS723) caused the dissociation of Dab2-CIN85 protein complex.
• Dab2-pS723 regulated ADP release and integrin aIIbb3 activation in thrombin-treated platelets.
Summary. Background: Disabled-2 (Dab2) is a platelet protein that is functionally involved in thrombin signaling in mice. It is unknown whether or not Dab2 undergoes phosphorylation during human platelet activation. Objectives: To investigate the phosphorylation status of Dab2 and its functional consequences in thrombin-stimulated human platelets. Methods: Dab2 was immunoprecipitated from resting and thrombin-stimulated platelet lysates for differential isotopic labeling. After enrichment of the phosphopeptides, the phosphorylation sites were analyzed by mass spectrometry. The corresponding phospho-specific antibody was generated. The protein kinases responsible for and the functional significance of Dab2 phosphorylation were defined by the use of signaling pathway inhibitors/activators, protein kinase assays, and various molecular approaches. Results: Dab2 was phosphorylated at Ser227, Ser394, Ser401 and Ser723 in thrombin-stimulated platelets, with Ser723 phosphorylation being the most significantly increased by thrombin. Dab2 was phosphorylated by protein kinase C at Ser723 in a G aq -dependent manner. ADP released from the stimulated platelets further activated the G bc -dependent pathway to sustain Ser723 phosphorylation. The Cbl-interacting protein of 85 kDa (CIN85) bound to Dab2 at a motif adjacent to Ser723 in resting platelets. The consequence of Ser723 phosphorylation was the dissociation of CIN85 from the Dab2-CIN85 complex. These molecular events led to increases in fibrinogen binding and platelet aggregation in thrombin-stimu
Introduction
Platelets play a pivotal role in hemostasis and pathologic thrombosis [1, 2] . Soluble agonists activate receptor-specific signaling pathways that converge into inside-out signaling of integrin a IIb b 3 . Fibrinogen ligation with integrin further induces outside-in signaling, leading to the cytoskeleton remodeling that is necessary for full platelet aggregation, spreading, and clot retraction [3, 4] . Thrombin is a platelet agonist that activates integrin signaling and modulates hemostasis and thrombosis [3] . Thrombin converts the event of proteolytic cleavage of thrombin receptors, which are G-proteincoupled protease-activated receptors (PARs), into a transmembrane signal to cause G aq -dependent activation of phospholipase Cb, leading to increases in intracellular calcium concentration and protein kinase C (PKC) activity, G a12/13 -dependent activation of Rho/ROCKII, G ai -dependent inhibition of adenylyl cyclase, and G bc -mediated activation of the phosphoinositide 3-kinase (PI3K)-Akt pathway. These events cause platelet shape change, granule secretion, arachidonic acid mobilization, and integrin activation [4, 5] . Impaired thrombin signaling has profound effects on hemostasis and thrombosis in vivo by prolonging the bleeding time and protecting the animal from systemic platelet activation and thrombosis [3, [6] [7] [8] [9] . Understanding the mechanism of how thrombin activates platelets is important in platelet biology, and may suggest new strategies for therapy.
Disabled-2 (Dab2) is an adaptor protein expressed in various cell types, including megakaryocytes and platelets [10] [11] [12] . Dab2 regulates receptor-mediated endocytosis, embryonic development, differentiation, signal transduction, the immune response and platelet activation through interactions with a variety of molecules [10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Dab2 has at least two alternative splicing isoforms (p82 and p59) [26, 27] . Human platelets express p82, whereas both p82 and p59 are detectable in rat platelets, and p59 is expressed in murine platelets [12] . A study on mouse platelets indicated that Dab2 function is linked to integrin activation and platelet signaling by Dab2 playing a selective role in the G a12/13 -mediated RhoA/ROCK activation underlying thrombin-stimulated inside-out signaling [12] . A study on human platelets indicated that Dab2 is distributed in both the cytosol and a-granules, and is released from the granular compartment upon platelet activation [11] . Two pools of Dab2 coexist at the platelet surface. Integrin-bound Dab2 inhibits platelet aggregation and is susceptible to thrombin-mediated proteolysis [11] . Dab2 is protected from cleavage by thrombin when it binds to sulfatide, and controls the extent of the clotting response [20] . Dab2 has been defined as a phosphoprotein, with its phosphorylation being linked to the control of integrin activation during 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced megakaryocytic differentiation of human leukemic K562 cells [10] . Whether or not and how Dab2 phosphorylation functions in thrombin signaling and integrin activation in platelets have yet to be elucidated.
Phosphoproteomic technology was used to analyze the status of Dab2 phosphorylation in thrombin-stimulated platelets. The Dab2 Ser723 phosphorylation site and the protein kinase responsible for the phosphorylation were defined. The functional significance of Dab2 Ser723 phosphorylation in thrombin signaling was determined.
Materials and methods

Materials
Fibrinogen, thrombin, ADP, Ral GDS-RBD agarose, and the anti-Rap1 antibody were purchased from Merck Millipore (Darmstadt, Germany). The Alexa Fluor 488-conjugated fibrinogen and the anti-phospho-integrin b3 (Tyr773) antibody were purchased from Invitrogen (Carlsbad, CA, USA). The antibodies against Dab2 (H110) and Cbl-interacting protein of 85 kDa (CIN85) (A7) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). The anti-Dab2 (p96) and fluorescein isothiocyanate (FITC)-labeled anti-human PAC-1 antibodies were purchased from BD Biosciences (San Diego, CA, USA). The phycoerythrin (PE)-labeled anti-CD62P antibody was purchased from eBioscience (San Diego, CA, USA). The CellTiter-Glo reagent was purchased from Promega (Madison, WI, USA). Apyrase, indomethacin and TPA were purchased from Sigma (St Louis, MO, USA). U46619 and prostaglandin I 2 (PGI 2 ) were purchased from Cayman Chemical (Ann Arbor, MI, USA). The anti-CIN85 (EPR7880 [2] ) and anti-Dab2 (EP2297Y) antibodies were purchased from Abcam (Cambridge, UK). The protein kinases used in this study were purchased from SignalChem (Richmond, BC, USA). Calf intestinal alkaline phosphatase (CIP) was purchased from New England Biolabs (Ipswich, MA, USA). Collagen was purchased from Chrono-Log (Havertown, PA, USA). The primers used in this study are shown in Table S1 . Details of the cloning procedures for plasmid constructs are available upon request.
Human washed platelet preparation and activation
The study was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital (Approval ID: 101-4744B). Human washed platelets were prepared and resuspended in Tyrode's buffer as described previously [28] . Platelets were activated by the indicated agonists at 37°C under stirring at 500 r.p.m.
Cell culture, transfection, immunoprecipitation, and western blot analysis
The 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and were transfected with plasmid DNA by use of Lipofectamine 2000 reagent as described previously [29, 30] . For immunoprecipitation, 2 mg of protein was incubated with 2 lg of antibody overnight at 4°C, and then incubated with protein G agarose at 4°C for 2.5 h. Alternatively, 2 mg of protein or 20 nmol of hemagglutinin (HA)-Dab2 peptides were incubated with anti-HA or anti-Flag agarose at 4°C for 2.5 h. The protein complexes were washed five times with 1 9 lysis buffer [17] , and eluted with 50 lL of 1 9 sample buffer for western blot analysis [31] .
Alkaline phosphatase assay
Human washed platelets were lysed in 1 9 CutSmart Buffer (New England Biolabs) containing 0.1% Triton X-100, 10 lg mL À1 aprotinin, 10 lg mL À1 leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Platelet lysates were incubated with CIP (20 units) at 30°C for 1 h. The reaction was stopped by adding 5 9 sample buffer. for thrombin-stimulated platelet lysates. The labeled samples were mixed in equal amounts, and this was followed by desalting and concentration with a reverse phase spin column. The samples were then analyzed with an UltiMate 3000 RSLCnano liquid chromatography (LC) system coupled to an Orbitrap Elite hybrid mass spectrometer (Thermo Fisher Scientific). More detailed information on the operation of the LC-tandem mass spectrometry system and the workflow of data analysis is available in the dataset of ProteomeXchange with the identifier PXD006337.
Fibrinogen-induced outside-in signaling assay
The 10-cm non-adhesive bacteriologic culture plates were precoated with 100 lg mL À1 fibrinogen. After blocking with heat-denatured 5% bovine serum albumin, 6 9 10 8 platelets were added to the plate and incubated at 37°C in a CO 2 incubator. After rinsing twice with Tyrode's buffer, the reaction was stopped, and the lysates of the platelets adherent to fibrinogen were prepared by adding 1 9 lysis buffer.
In vitro protein kinase assay
In vitro protein kinase assays with the wild-type (WT) (KPAPRQVSLPVAK) or mutant (MT) (KPAPRQ-VALPVAK) peptide substrates were performed by Kinexus Bioinformatics (Vancouver, BC, Canada) according to the manufacturer's standard protocol. In addition, HA-Dab2 or HA-Dab2-S723A was immunoprecipitated by the use of anti-HA agarose beads from 293T cells overexpressing the indicated Dab2 proteins. Phosphorylation assays were performed by incubating the immunoprecipitated proteins with the kinase buffer [32] in the presence of the indicated protein kinases at 30°C for 30 min. The assay was then terminated by adding 5 9 sample buffer.
Dot blot assay
The peptides (20 nmol) were spotted onto the nitrocellulose membrane. The membrane was air-dried and blocked with 5% non-fat milk and 0.05% Tween-20 in Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 30 min, and this was followed by protein detection as described for western blot analysis.
Delivery of cell-penetrating peptides (CPPs)
Washed platelets were incubated with the indicated concentrations of CPPs at 37°C for 20 min. After washing with Tyrode's buffer containing PGI 2 (0.3 lg mL
À1
) and apyrase (0.02 U mL À1 ), platelets were collected by centrifugation at 980 9 g for 10 min and resuspended in Tyrode's buffer.
Flow cytometry analysis
Agonist-stimulated platelets were incubated with either PE-conjugated anti-CD62P antibody, FITC-labeled antihuman PAC-1 antibody or Alexa Fluor 488-conjugated fibrinogen for 20 min at room temperature in the dark. The reactions were stopped by addition of cold 1 9 phosphate-buffered saline, and the samples were analyzed within 30 min by use of the Accuri C6 Flow Cytometer with CFLOW software (BD Biosciences).
Measurement of ADP release
Washed platelets were incubated with CellTiter-Glo reagent (A), potassium acetate/pyruvate kinase/phospho (enol)pyruvic acid tri(cyclohexylammonium) mixture (B), ATP (0.001 pmol, C) and ADP (0.001 pmol, D) at room temperature for 10 min. The luminescent signal was measured as described previously [12] . The ADP content for each sample was calculated by use of the following equation: ADP (pmol) = 0.001 9 (B -A)/(C -B). The value of 100 9 (D -C)/(B -C) was used as the quality control within the acceptable range of 100 AE 10.
Rap1 activity assay
An equal volume of 2 9 Rap1 lysis buffer [33] was added to the platelet suspension and incubated on ice for 30 min. A total of 0.5 mg of protein was incubated with Ral GDS-RBD agarose at 4°C for 45 min. After washing of the beads three times with 1 9 Rap1 lysis buffer, the GTP-bound Rap1 proteins were eluted with 2 9 sample buffer with 50 mM dithiothreitol at 95°C for 5 min.
Statistical analysis
Student's t-test was used for all analyses. The data were presented as mean AE standard error of the mean. P < 0.05 was considered to be statistically significant.
Results
Dab2 Ser723 phosphorylation upon thrombin-induced human platelet activation
Dab2 protein mobility was retarded when the lysates from human platelets treated with thrombin, PAR1 peptide (SFLLRN) and PAR4 peptide (AYPGKF) were analyzed by SDS-PAGE (Fig. 1A) . The retardation of Dab2 protein mobility was reversed when the thrombin-stimulated and PAR4 peptide-stimulated platelet lysates were preincubated with CIP. The phosphatase inhibitors Na 3 VO 4 and NaF reversed the effects of CIP on Dab2 mobility retardation (Fig. 1B ). These data indicate that Dab2 undergoes phosphorylation when human platelets are stimulated by thrombin-related agonists. Dab2 was enriched by immunoprecipitation from resting and thrombin-stimulated platelet lysates to define its thrombin-induced phosphorylation site(s) (Fig. 2A) . The coverage of Dab2 peptides was 39.6%, and six phosphoDab2 peptides were detected by mass spectrometry ( Fig. 2B ; Table S2 ). The phospho-Dab2 peptide QVS(ph) LPVTK corresponded to amino acids 721-728. The intensity of Dab2 Ser723 phosphorylation in thrombin-stimulated platelets was 31.1-fold greater than in resting platelets. The other phospho-Dab2 peptides corresponded to the Ser227, Ser394 and Ser401 phosphorylation sites (Table S2 ). Dab2 Ser723 is conserved in humans, chimpanzees, rhesus macaques, and dogs, but not in rats, mice, hamsters, platypuses, chickens, frogs, and zebrafish (Table S3 ), indicating that thrombin-induced Dab2 Ser723 phosphorylation is present in the platelets of humans and other higher mammals, but not in rodents.
Dab2 Ser723 phosphorylation occurs in thrombin-induced inside-out signaling of integrin
A rabbit anti-human Dab2 phospho-Ser723-specific [antip-Dab2 (S723)] antibody was generated to facilitate the detection and analysis of Dab2 Ser723 phosphorylation ( Fig. S1A-D) . A dose-dependent increase in Dab2 Ser723 phosphorylation was found when human platelets were treated with thrombin, PAR1 peptide, and PAR4 peptide (Fig. 3A) . Dab2 Ser723 phosphorylation occurred at 15 s, peaked at 2 min and was sustained for > 10 min after thrombin stimulation (Fig. 3B ). RGDS peptide [11] suppressed fibrinogen binding to integrin a IIb b 3 of the thrombin-activated platelets ( Fig. 3C; Fig. S2 ). The level of Dab2 Ser723 phosphorylation in thrombin-stimulated human platelets was the same whether or not platelets were preincubated with RGDS peptide (Fig. 3D ). When outside-in signaling was directly induced by spreading of human platelets on fibrinogen, as shown by the phosphorylation of integrin b 3 Y773, Dab2 Ser723 was not phosphorylated (Fig. 3E ). These data indicate that Dab2 Ser723 phosphorylation occurs in thrombin-stimulated platelets upstream of integrin outside-in signaling.
Thrombin-stimulated Dab2 Ser723 phosphorylation was suppressed when human platelets were preincubated with the ADP inhibitor apyrase (Fig. 4A ). Indomethacin, a cyclooxygenase inhibitor that inhibits prostaglandin synthesis and thromboxane A 2 (TXA 2 ) generation, had a moderate but not statistically significant inhibitory effect on thrombin-stimulated Dab2 Ser723 phosphorylation (Fig. 4A) . Stimulation of platelets with the TXA 2 agonist U46619 and ADP induced Dab2 Ser723 phosphorylation (Fig. 4B) . Stimulation of platelets with SC79 [34] , which activated Akt underlying the G bc -dependent pathway, also caused an increase in Dab2 Ser723 phosphorylation (Fig. 4C ). These data indicate that both ADP and TXA 2 induce Dab2 Ser723 phosphorylation, but only ADP facilitates Dab2 Ser723 phosphorylation in thrombin-stimulated platelets.
PKC is responsible for Dab2 Ser723 phosphorylation in human platelets
Protein kinases that are involved in thrombin signaling and have the consensus substrate motif of Arg/Lys-X-(X)-Ser/Thr corresponding to Dab2 Ser723 and its flanking sequences (RQVSLPVTK) were selected to determine whether or not they are responsible for Dab2 Ser723 phosphorylation (Table S4 ). The protein kinases calmodulin-dependent protein kinase 2c (CaMK2c), PKCa, and ROCKII, but not Akt1, Akt2, Akt3, and p70S6Kb, phosphorylated the WT peptide (phosphorylation activity > 50 000 c.p.m.) in vitro ( Fig. 5A ; Table S5 ). The phosphorylation of the peptide substrate by CaMK2c, PKCa and ROCKII was diminished when Ser723 was mutated to Ala723 (MT peptide). ROCKI, an isoform of ROCKII, phosphorylated the WT peptide with less kinase-specific activity (Fig. 5A) . Consistent with these findings, ROCKII, CaMK2c and the PKC isoforms a, bII, d and h caused Dab2 Ser723 phosphorylation when full-length HA-Dab2 recombinant protein was used as the substrate. The phosphorylation was abolished when Ser723 was mutated to Ala723 ( Fig. 5B; Fig. S3A ). Although the PRQVS 723 LPVTK sequence of Dab2 is consistent with the consensus substrate motif of Akt (X-R-X-X-S/T) [35] and myosin light chain kinase (X-R-X-X-S-φ-φ-φ) [36] , they were not responsible for Dab2 Ser723 phosphorylation ( Fig. 5B; Fig. S3B ). These data indicate that PKCs, CaMK2c and ROCKII are the in vitro protein kinases for the phosphorylation of Dab2 Ser723.
Pretreatment of human platelets with U73122 (an inhibitor of phospholipase C [PLC] activation), staurosporine (a PKC inhibitor) and W-7 (a calmodulin inhibitor), but not KN62 (a calmodulin-dependent protein kinase II inhibitor), Y27632, and HA-1100 (ROCK inhibitors), suppressed thrombin-stimulated Dab2 Ser723 phosphorylation (Fig. 5C ). Dab2 Ser723 is more likely to be phosphorylated by PKCs underlying the G aq -dependent PLC-PKC pathway and less likely to be phosphorylated by CaMK2c of the G aq -dependent pathway and ROCKII of the G a12/13 -dependent pathway. This notion was reinforced by the observation that direct activation of PKC , 200 lL) were added to an Eppendorf tube and stimulated with the indicated agonists at 37°C for 10 min with constant stirring at 500 r.p.m. After addition of 5 9 lysis buffer (50 mM Tris-HCl [pH 7.4], 500 mM NaCl, 2.5 mM CaCl 2 , 2.5 mM MgCl 2 , 5% Triton X-100, 50 lg mL À1 aprotinin, 50 lg mL À1 leupeptin, 5 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 50 mM NaF, and 5 mM EGTA), by TPA induced Dab2 Ser723 phosphorylation in a dosedependent manner (Fig. 5D) . PKC activation by collagen also resulted in Dab2 Ser723 phosphorylation (Fig. S4) . PKC is the protein kinase responsible for Dab2 Ser723 phosphorylation during platelet activation.
Dab2 Ser723 phosphorylation causes the dissociation of Dab2 and CIN85 during thrombin-stimulated platelet activation
Dab2 binds the Src homology 3 domain of CIN85 through the 715 PKPAPR 720 amino acids [37] . Two immunoreactive bands were recognized by the anti-CIN85 antibody (A7) in human platelets. Dab2 was coimmunoprecipitated with the CIN85 of higher molecular mass at the resting stage of human platelets. The Dab2-CIN85 interaction was decreased by 53.4% in thrombin-stimulated platelets (Fig. 6A) . The Dab2-CIN85 interaction was confirmed by coimmunoprecipitation of Dab2 with endogenous and exogenous CIN85 in 293T cells (Fig. 6B) . The interaction of CIN85 with the recombinant HA-Dab2-S723D protein mimicking constitutive Dab2 Ser723 phosphorylation was decreased as compared with WT HA-Dab2 and the HA-Dab2-S723A recombinant protein (Fig. 6C) . Only peptide C (HA-tag peptide containing non-phosphorylated Ser723 and the CIN85- binding site), and not peptide P (HA-tag peptide containing phosphorylated Ser723 and the CIN85-binding site) and peptide N (HA-tag peptide containing non-phosphorylated Ser723 without the CIN85-binding site) (Table S6) , was able to immunoprecipitate CIN85 that was exogenously expressed in 293T cells (Fig. 6D ). These data indicate that Dab2 Ser723 phosphorylation interferes with the interactions of Dab2 and CIN85. (S723) antibodies. The expression of b-actin was used as a control for equal protein loading. The relative level of Dab2 Ser723 phosphorylation was quantified with IMAGEJ software, and the data represent the mean AE standard error of the mean (SEM) of five to seven independent experiments. **P < 0.01; ***P < 0.001. (B) Human platelets (3 9 10 8 mL À1 ) were stimulated with different concentrations of the indicated agonists for 10 min. The platelet lysates were collected for western blot analysis with anti-Dab2 (p96) and anti-p-Dab2 (S723) antibodies. The expression of b-actin was used as a control for equal protein loading. Representative data for at least three independent experiments are shown. (C) Human platelets (3 9 10 8 mL À1 ) were incubated with SC79 (4 lg mL À1 ) for the indicated time. The platelet lysates were subjected to western blot analysis with the indicated antibodies. The relative level of Dab2 Ser723 phosphorylation was quantified with IMAGEJ software, and the data represent the mean AE SEM of three independent experiments. *P < 0.05. DMSO, dimethyl sulfoxide. ) were pretreated with the indicated protein kinase inhibitors for 10 min, and then subjected to thrombin (0.25 U mL À1 ) stimulation at 37°C for 2 min with stirring at 500 r.p.m. The platelet lysates were subjected to western blot analysis with the indicated antibodies.
The expression of b-actin was used as a control for equal protein loading. The relative level of Dab2 Ser723 phosphorylation was quantified with IMAGEJ software. The data represent the mean AE standard error of the mean of three to five independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (D) Human platelets (3 9 10 8 mL
À1
) were stimulated with different concentrations of 12-O-tetradecanoylphorbol-13-acetate (TPA) for 10 min. The platelet lysates were subjected to western blot analysis with the indicated antibodies. The expression of bactin was used as a control for equal protein loading. Representative data for at least three independent experiments are shown. CamMK2c, calmodulin-dependent protein kinase 2c; NS, not significant; PKCa, protein kinase Ca; Th, thrombin.
Dab2-derived peptide containing the CIN85-binding motif suppresses thrombin-stimulated ADP release and integrin a IIb b 3 activation Peptide C but not peptide N decreased the interaction of Dab2 with CIN85 by 63.6% as compared with the control in the absence of any peptide (Fig. S5) . These data indicate that peptide C sequesters CIN85 and acts as a competitive peptide for the interaction of Dab2 and CIN85. The peptides containing 11 repeats of arginine (R11) acted as CPPs with no cytotoxicity to the platelets up to 50 lM, and had better efficiency than the peptides with nine repeats of arginine (R9) in the delivery of macromolecules such as the fluorochrome FITC into the platelets (Fig. S6A-C) . R11 was linked to the Dab2 sequences of peptide C or peptide N with replacement of Ser to Ala at the amino acid position 723 (R11-C or R11-N) for peptide delivery into platelets to explore the consequences of Dab2 Ser723 phosphorylation for platelet function (Table S6 ). The mutation of Ser723 to Ala723 prevented the peptide from phosphorylation in platelets, but the ability to bind and sequester CIN85 was retained (Fig. S7) . Preincubation of platelets with R11-C inhibited thrombin-induced PAC-1 and fibrinogen binding, platelet aggregation and ADP release as compared with platelets preincubated with mock, R11, and R11-N (Fig. 7A-D) . R11-C had no effect on a-granule secretion or Rap1 activation (Fig. 7E,F) , which is involved in the regulation of thrombin-stimulated integrin activation. These data imply that CIN85 released from the Dab2-CIN85 complex is involved in the regulation of ADP release and inside-out signaling of integrin a IIb b 3 independently of Rap1 activation.
Discussion
Human platelet Dab2 was identified as a phosphoprotein in this study. Dab2 Ser723 phosphorylation underlies thrombin-stimulated inside-out signaling of integrin and, by regulating the interaction between Dab2 and CIN85, provides an alternative pathway in the control of ADP/ dense granule release, fibrinogen binding, platelet aggregation, and integrin a IIb b 3 activation.
A number of Dab2 phosphorylation sites, including Ser24, Ser448, Ser449, Ser723 and clusters of phosphorylation sites in amino acids 221-231, 324-329 and 393-401 play important roles in integrin activation, endocytosis, and mitosis [10, 27, 32, [38] [39] [40] . Dab2 was phosphorylated at Ser227, Ser394, Ser401 and Ser723 in thrombin-stimulated human platelets, with Ser723 phosphorylation being most significantly increased by thrombin. Dab2 Ser723 was shown for the first time in vitro to be a substrate of the classic and novel isoforms of PKCs, CaMK2c, and ROCKII. Inhibitor studies indicated that PKC was the protein kinase responsible for thrombin-stimulated Dab2 Ser723 phosphorylation. This is based on the findings with different Dab2-derived peptides (10 lM) at 37°C for 20 min, and then washed with Tyrode's buffer. After 30 min, human platelets were stimulated with thrombin (0.25 U mL À1 ), and platelet aggregation was recorded with a platelet aggregometer (Chrono-Log) for 2 min. The data represent the mean AE SEM of seven independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (D, E) Human platelets (3 9 10 8 mL
À1
) were incubated with different Dab2-derived peptides (10 lM) at 37°C for 20 min, and then washed with Tyrode's buffer. After 30 min, human platelets were stimulated with thrombin (0.25 U mL À1 ) for 2 min, incubated with 5 lL of the phycoerythrin-conjugated CD62P antibody, and then subjected to flow cytometry (E). The supernatants were collected for the ADP release assay (D). The data represent the mean AE SEM of 7-10 independent experiments. *P < 0.05; ***P < 0.001. (F) Human platelets (3 9 10 8 mL
) were incubated with different Dab2-derived peptides (10 lM) at 37°C for 20 min, and then washed with Tyrode's buffer. After 30 min, human platelets were stimulated with thrombin (0.25 U mL
) for 2 min. Lysates were prepared and subjected to immunoprecipitation with Ral GDS-RBD agarose (30 lL). The immunoprecipitated proteins were analyzed by western blotting with the indicated antibodies. The data represent the mean AE SEM of three independent experiments. that staurosporine (PKC inhibitor) but not KN62 (CaMK2c inhibitor) and Y27632 and HA-1100 (ROCKII inhibitors) suppressed thrombin-stimulated Dab2 Ser723 phosphorylation in platelets. The inhibitory effect of another CaMK2c inhibitor, W-7, on Ser723 phosphorylation was probably related to its suppressive activity on calcium mobilization [41] , leading to indirect inhibition of calcium-dependent activation of PKC. In other cell types, CaMK2c and ROCKII may serve a similar function as the protein kinases of Ser723.
The signaling pathways underlying thrombin-induced Dab2 Ser723 phosphorylation was investigated. U73122, an inhibitor of PLC activation, suppressed Dab2 Ser723 phosphorylation. The ADP-removing enzyme apyrase and the Akt activator SC79 decreased and increased Dab2 Ser723 phosphorylation, respectively. Inhibition of TXA 2 generation by indomethacin did not decrease thrombin-stimulated Dab2 Ser723 phosphorylation. This is consistent with the model in which platelets are activated via a mechanism that is insensitive to indomethacin at high concentrations of thrombin [42] . On the basis of these findings, two signaling pathways are proposed to transmit thrombin signals leading to PKC activation and Dab2 Ser723 phosphorylation. G aq -dependent activation of PLCb represents the first signaling pathway to activate PKC, followed by Ser723 phosphorylation of Dab2 in thrombin-stimulated platelets. ADP release and the subsequent activation of G bc -dependent signaling represent the second pathway, which leads to increases in intracellular calcium levels and PKC activation [43] [44] [45] [46] , and Ser723 phosphorylation of Dab2. Because Akt is a protein kinase downstream of ADP signaling but is not the protein kinase for phosphorylation of Dab2 Ser723, PI3K-Akt-mediated PKC activation [47] is a plausible mechanism for Ser723 phosphorylation of Dab2 in response to thrombin stimulation. This mode of action explains why ADP release but not TXA 2 generation is involved in thrombin-stimulated Dab2 Ser723 phosphorylation, whereas both ADP and the TXA 2 agonist U46619 induced the phosphorylation of Dab2 Ser723. Together with the finding that Dab2 Ser723 was not phosphorylated in platelets adhering to fibrinogen, this indicates that Dab2 Ser723 phosphorylation is part of the mechanism for inside-out signaling of integrin in response to thrombin stimulation.
CIN85 is a Dab2 binding partner [37] and is involved in T-cell and B-cell receptor signaling, the internalization of epidermal growth factor receptor and IgE receptor, cell adhesion, and outside-in signaling of integrin [37, [48] [49] [50] [51] . The permeable peptide R11-C sequestered CIN85 released from Ser723-phosphorylated Dab2 and inhibited thrombin-induced PAC-1 and fibrinogen binding, platelet aggregation, and ADP/dense granule release, but had no effect on a-granule secretion or Rap1 activation. These findings are consistent with the role of PKC in integrin activation and granule secretion [52, 53] . PKC activates Rap1 and regulates talin binding to the cytoplasmic tail of integrin a IIb b 3 [52] . However, integrin a IIb b 3 activation is not completely inhibited in Rap1b knockout platelets [54] . These studies, together with our findings, imply that Dab2-CIN85 regulates thrombin-induced integrin activation through a Rap1b-independent pathway. On the other hand, a-granule and dense granule secretion is regulated by common machinery involving a 'core' SNARE complex [55] and PKC-mediated phosphorylation of syntaxin-4, Munc-18, and glycogen synthase kinase-3b (GSK3b) [56] [57] [58] . Rab27b, protein kinase D2 and syntaxin-8 regulate the secretion of platelet dense granules but not that of a-granules [59] [60] [61] . Disruption of the actin cytoskeleton by a low concentration of latrunculin A results in augmentation of a-granule secretion induced by PAR-1 peptide, but fails to influence dense granule release. A high concentration of latrunculin A stimulates dense granule release [62] . Dab2 Ser723 phosphorylation and the interaction of Dab2 with CIN85 were identified as part of the machinery controlling ADP/dense granule secretion. This is consistent with a study on Dab2 knockout mice demonstrating that Dab2 À/À platelets are defective in ADP release [12] . Dab2 expression and the dissociation of CIN85 from Ser723-phosphorylated Dab2 play important roles in dense granule/ADP release and Rap1-independent integrin activation, representing a novel mechanism for the regulation of platelet activation. This study raises several questions that can be further addressed. First, the definitive molecular events that are followed by sequestering of CIN85 by R11-C remain to be elucidated. Both Dab2 and CIN85 interact with cytoskeleton proteins [27, 63, 64] and are related to dense granule secretion [62] and integrin activation [65] [66] [67] . CIN85 released from the Dab2-CIN85 complex may be incorporated into a protein complex involving cytoskeleton proteins. c-Cbl and the catalytic subunit of protein phosphatase 2A (PP2Ac) are the CIN85-binding partners that are the components of the protein interactome related to the control of cytoskeleton reorganization [68, 69] and integrin signaling in human platelets [48, 70, 71] . The CIN85-c-Cbl interaction was decreased after thrombin stimulation, whereas the CIN85-PP2Ac interaction was not detected (Figs S8 and S9) . The detailed molecular consequences of the release of CIN85 from the Dab2-CIN85 complex still require further investigation. Second, Dab2 Ser723 phosphorylation, unlike in thrombin-stimulated platelets, was uncoupled from platelet aggregation in collagen-stimulated, U46619-stimulated and ADP-stimulated platelets (Fig. S10 ). Dab2 Ser249 phosphorylation was detected in resting and activated platelets induced by ADP [72] but not thrombin (Table S2 ). The interplay of Ser723 with other phosphorylation sites may provide a new regulatory function of Dab2 in integrin activation. Finally, mouse Dab2 does not carry the amino acid Ser723. Whether or not Dab2 is constitutively associated with CIN85 in mouse platelets or Dab2-CIN85 complex dissociation is regulated by a different mechanism independently of Dab2 Ser723 phosphorylation is not clear. CIN85 phosphorylation controls its interaction with Disabled-1 [73] . Regulation of the mouse Dab2-CIN85 interaction by CIN85 phosphorylation is a plausible explanation, but needs to be further addressed.
As illustrated in Fig. 8 , Dab2 forms a protein complex with CIN85 in resting human platelets. PKC-mediated Dab2 Ser723 phosphorylation causes dissociation of the Dab2-CIN85 complex in thrombin-stimulated platelets. CIN85 released from the protein complex acts on the signaling pathways related to integrin a IIb b 3 activation, fibrinogen binding, platelet aggregation, and ADP release. Novel evidence is presented showing that Dab2 Ser723 phosphorylation is a key molecular event in thrombin-stimulated inside-out signaling and platelet activation, and sheds light on the molecular basis of integrin activation in human platelets. Gung University). This work was supported partially by Ministry of Science and Technology (Taiwan) grants 105-2320-B-182-030 and 105-2320-B-182-029-MY3 to C.-P. Tseng, and Chang Gung Memorial Hospital grants CLRPD190016 to the Proteomics Core Laboratory, and CMRPD1C0551-3, CMRPD1E0181-3, CMRPD1F0611 and BMRP466 to C.-P. Tseng.
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